NCT06698003 2026-03-05
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06235281 2026-02-27
PLIGHT
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Suspended
NCT04848064 2026-02-10
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT05956041 2026-01-07
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT04541017 2025-10-16
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04930653 2025-10-14
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06285370 2025-09-18
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Kyowa Kirin Co., Ltd.
Phase 4 Active not recruiting
NCT05414500 2025-08-08
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
Phase 1 Recruiting
NCT04256018 2025-07-02
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
Phase 2 Recruiting